REG - Oxford Nanopore Tech - Changes in Composition of Remuneration Committee

Oxford Nanopore TechnologiesAnnouncement

05/06/2025 18:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250605:nRSE6801La&default-theme=true

RNS Number : 6801L  Oxford Nanopore Technologies plc  05 June 2025

05 June 2025

Oxford Nanopore Technologies plc

(the "Company")

Changes in Composition of the Remuneration Committee

The Company is pleased to announce that Heather Preston has been appointed as
Chair of the Remuneration Committee with immediate effect. Heather has been a
Non-Executive Director of the Company since 19 December 2023 and is also a
member of the Nomination Committee.

Heather succeeds John O'Higgins who stands down as Interim Chair of the
Remuneration Committee but remains a Remuneration Committee, Nomination
Committee, and Audit & Risk Committee member. The Board would like to
thank John O'Higgins for his wise counsel and committed leadership in this
role from 10 June 2024 to date.

This announcement has been made pursuant to the UK Listing Rule 6.4.6R.

 

-ENDS-

For further information please contact:

cosec@nanoporetech.com

ir@nanoporetech.com

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
faster, information rich, accessible and affordable molecular analysis. The
first application is DNA/RNA sequencing, and the technology is in development
for the analysis of other types of molecules including proteins. The
technology is used in more than 125 countries to understand and characterise
the biology of humans and diseases such as cancer, plants, animals, bacteria,
viruses, and whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended for
diagnostic purposes. For more information, please
visit: https://nanoporetech.com/ (https://nanoporetech.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUMCQUPAGQA